News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Furiex Pharmaceuticals, Inc. (FURX) Confirms Takeda Pharmaceutical Co. Ltd. (TKPYY) Will Present Additional Data From The EXAMINE Trial At The American College of Cardiology’s 63rd Annual Scientific Session


3/27/2014 10:23:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that its partner Takeda Pharmaceuticals Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s (ACC) 63rd Annual Scientific Session in Washington, DC.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES